---
figid: PMC5206990__nihms836683f3
figtitle: Rationale for combination therapy in lymphoma
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC5206990
filename: nihms836683f3.jpg
figlink: /pmc/articles/PMC5206990/figure/F3/
number: F3
caption: Rationale for combination therapy in lymphoma. Lymphoma cells frequently
  use several activated oncogenic pathways to promote their growth and survival. In
  some cases, activation of one receptor or several receptors is involved in the oncogenic
  process. Furthermore, within one pathway, such as the PI3K/AKT/mTOR pathway, several
  proteins can be therapeutically targeted.
papertitle: From drug discovery to biomarker-driven clinical trials in lymphoma.
reftext: Anas Younes, et al. Nat Rev Clin Oncol. ;9(11):643-653.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9820666
figid_alias: PMC5206990__F3
figtype: Figure
redirect_from: /figures/PMC5206990__F3
ndex: 7dcd6492-deb9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5206990__nihms836683f3.html
  '@type': Dataset
  description: Rationale for combination therapy in lymphoma. Lymphoma cells frequently
    use several activated oncogenic pathways to promote their growth and survival.
    In some cases, activation of one receptor or several receptors is involved in
    the oncogenic process. Furthermore, within one pathway, such as the PI3K/AKT/mTOR
    pathway, several proteins can be therapeutically targeted.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - tnfb
  - kita
  - ngfra
  - pak2a
  - itpka
  - tnfrsfa
  - bcr
  - il6
  - il10
  - vegfaa
  - cd40
  - jak2b
  - jak1
  - lyn
  - si:ch73-206d17.1
  - syk
  - btk
  - stat1b
  - stat4
  - mtor
  - cd79b
  - cd79a
  - TNFSF13B
  - CD40LG
  - TNF
  - BCR
  - RN7SL263P
  - IL6
  - IL10
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TNFRSF1A
  - TNFRSF13C
  - CD40
  - JAK2
  - JAK1
  - LYN
  - SYK
  - BTK
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - NFKB1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MTOR
  - CD79B
  - CD79A
  - tyrosine
  - Cancer
---
